Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Today eight Oxford University academics have been awarded significant financial funding from the UKRI ‘Future Leaders Fellowships scheme’ that was created to help develop the next wave of world-class research and innovation leaders in academia and business. Science Minister Amanda Solloway announced nearly 100 new Fellows, who will share in £113 million funding, with individual researchers receiving up to £1.5 million.

The eight winners from the University of Oxford include Dr Regent Lee (Nuffield Department of Surgical Sciences) and Dr Alexander Davies (Nuffield Department of Clinical Neurosciences).

Dr Regent Lee is a is a vascular surgeon and a clinician scientist. His research focuses on integrative assessments to define novel precision management for patients with abdominal aortic aneurysms (AAA) – a condition that kills about 200,000 people globally each year. He will be developing novel blood and imaging tests to improve the management of these patients, as well as developing platform technologies that can be applied to other disease contexts.

During his fellowship, Dr Alex Davies and his team will investigate exactly how ‘killer’ cells target injured nerves, with the aim of developing a targeted immune therapy for neuropathic pain that avoids the side effects of existing treatments.

Chronic pain, often because of nerve injury, affects as many as 1 in 3 adults in the UK and costs the economy billions of pounds every year in treatment and lost productivity. The currently used drugs may either be ineffective or pose significant side effects for patients. Dr Davies’s previous research has shown that injured nerves display distress signals that are received by specialised ‘killer’ cells of the immune system. The activity of these killer immune cells in turn appears to help relieve the pain of a nerve injury.

Read the full story, including details of other Oxford winners, on the University of Oxford website

Read more about Dr Alexander Davies’s fellowship on the Nuffield Department of Clinical Neurosciences website

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

20 minutes of daily exercise can keep teens' doctors away

Teenagers should exercise vigorously for at least 20 minutes per day to reap increased cardiorespiratory fitness (CRF), according to a cross-sectional study from the UK led by University of Oxford researchers.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.